Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors

Traditional CAR-T cells, while effective against liquid cancers, face challenges in solid tumors: the cells wear out and ultimately fail to destroy the cancer completely. Ground-breaking research is providing an innovative approach to this challenge. Researchers are introducing CAR-T cells that excrete the IL-10 molecule. In other words, the cell has been designed to produce its own “drug” to stay healthy in the tumor’s hostile environment. In the laboratory, this innovative CAR-T therapy systematically eradicated cancerous tumors in mouse models. What’s more, in ongoing clinical trials, eleven patients have appeared to achieve complete remission with this treatment, representing a 100% success rate to date. Notably, the evidence from the laboratory study suggests the long-term efficacy of the therapy, and indicates that its manufacture could be both faster and more cost-effective than current methods.

Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors - Blog

Share :

Tags :